Stereotactic surgery

Helsinki University Hospital Selects MRIdian® System for Installation at Comprehensive Cancer Center

Retrieved on: 
Monday, October 25, 2021
Magnetic resonance imaging, Lung, Cancer, Coronavirus, OECI, Research, Technology, 2021 Essex County Council election, Radiation, Hospital, Industry, Prostate, Neoplasm, Liver cancer, Organization, Roswell Park Comprehensive Cancer Center, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, Stereotactic surgery, Accreditation, Irritation, SEC, Nausea, NCI-designated Cancer Center, Annual report, Hair loss, Company, Fatigue, COVID-19, Pancreas, Skin, Nasdaq, Organisation of European Cancer Institutes, Toxicity, Pulmonary toxicity, Field line, Physician, Medical device, Medical imaging

CLEVELAND, Oct. 25, 2021 /PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) today announcedthat Helsinki University Hospital has purchased a MRIdian System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital.

Key Points: 
  • CLEVELAND, Oct. 25, 2021 /PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) today announcedthat Helsinki University Hospital has purchased a MRIdian System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital.
  • The Comprehensive Cancer Center is Finland's largest and most versatile cancer treatment center.
  • The Comprehensive Cancer Center is the first Nordic cancer center to have undergone accreditation through the Organisation of European Cancer Institutes (OECI) and achieved the highest possible status of a Comprehensive Cancer Center.
  • "We are proud to have Helsinki University Hospital join the MRIdian community," said Paul Ziegler, Chief Commercial Officer at ViewRay.

Helsinki University Hospital Selects MRIdian® System for Installation at Comprehensive Cancer Center

Retrieved on: 
Monday, October 25, 2021
Magnetic resonance imaging, Lung, Cancer, Coronavirus, OECI, Research, Technology, 2021 Essex County Council election, Radiation, Hospital, Industry, Prostate, Neoplasm, Liver cancer, Organization, Roswell Park Comprehensive Cancer Center, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, NASDAQ, Stereotactic surgery, Accreditation, Irritation, SEC, Nausea, NCI-designated Cancer Center, Annual report, Hair loss, Company, Fatigue, COVID-19, Pancreas, Skin, Nasdaq, Organisation of European Cancer Institutes, Toxicity, Pulmonary toxicity, Field line, Physician, Medical device, Medical imaging

CLEVELAND, Oct. 25, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Helsinki University Hospital has purchased a MRIdian® System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital.

Key Points: 
  • CLEVELAND, Oct. 25, 2021 /PRNewswire/ --ViewRay, Inc. (NASDAQ: VRAY) today announcedthat Helsinki University Hospital has purchased a MRIdian System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital.
  • The Comprehensive Cancer Center is Finland's largest and most versatile cancer treatment center.
  • The Comprehensive Cancer Center is the first Nordic cancer center to have undergone accreditation through the Organisation of European Cancer Institutes (OECI) and achieved the highest possible status of a Comprehensive Cancer Center.
  • "We are proud to have Helsinki University Hospital join the MRIdian community," said Paul Ziegler, Chief Commercial Officer at ViewRay.

ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations

Retrieved on: 
Wednesday, September 29, 2021
Field line, Irritation, Cancer, Radiation, MRI, 2021 Essex County Council election, Efficiency, Toxic leukoencephalopathy, Fatigue, Hair loss, Annual report, Security (finance), Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, FDA, Patient, Physician, Hospital, Nausea, Toxicity, CEO, Magnetic resonance imaging, Industry, Coronavirus, Company, COVID-19, Technology, Research, Nasdaq, SEC, Skin, Stereotactic surgery, Pharmaceutical industry, Medical imaging

The submission also includes a new brain treatment package and the integration of a real-time patient feedback display.

Key Points: 
  • The submission also includes a new brain treatment package and the integration of a real-time patient feedback display.
  • The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
  • ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian MRI-Guided Radiation Therapy System.
  • ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Global Mammography Systems Market (2021 to 2029) - Featuring Hologic, Phillips Healthcare and Toshiba Medical Systems Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Health, Oncology, Medical devices, Clinical medicine, Medicine, Medical specialties, Biopsy, Cancer screening, Breast imaging, Mammography, Projectional radiography, Breast biopsy, Stereotactic surgery, Breast cancer, Planmed

Factors such as booming healthcare industry with developing healthcare infrastructure and rising investments, government initiatives and mounting awareness regarding regular monitoring and diagnosis are fuelling the global mammography systems market.

Key Points: 
  • Factors such as booming healthcare industry with developing healthcare infrastructure and rising investments, government initiatives and mounting awareness regarding regular monitoring and diagnosis are fuelling the global mammography systems market.
  • The products segment includes screen film mammography, digital mammography systems, analog mammography systems, stereotactic breast biopsy, and 3D mammography systems.
  • To assess the market competition, company profiling and market positioning of leading participants in the global mammography systems have been provided in the report.
  • Company profiling of major market players is done based on business overview, financial analysis, product portfolio and key recent developments of each company operating in the mammography systems market.

Demand for Precise and Effective Treatment Accelerating Stereotactic Planning Software Spending Analysis Market Growth: Future Market Insights Study

Retrieved on: 
Wednesday, June 9, 2021
Medicine, Clinical medicine, Medical specialties, Neurosurgery, Computer-assisted surgery, Biopsy, Stereotactic surgery, Surgical oncology, Minimally invasive procedure, Surgeon

DUBAI, U.A.E, June 9, 2021 /PRNewswire/ -- The global stereotactic planning software spending analysis market is forecast to expand at 4.6% CAGR between 2021 and 2031, as per ESOMAR-certified consulting firm Future Market Insights (FMI).

Key Points: 
  • DUBAI, U.A.E, June 9, 2021 /PRNewswire/ -- The global stereotactic planning software spending analysis market is forecast to expand at 4.6% CAGR between 2021 and 2031, as per ESOMAR-certified consulting firm Future Market Insights (FMI).
  • Increasing demand for minimally-invasive treatment options has fueled the adoption of stereotactic planning software.
  • With the help of stereotactic planning software, surgeons will be able to perform surgery with reduced trajectory planning time.
  • COVID-19 pandemic hindered the stereotactic planning software spending market amid implementation of lockdown, limited production, and travel restrictions.

Demand for Precise and Effective Treatment Accelerating Stereotactic Planning Software Spending Analysis Market Growth: Future Market Insights Study

Retrieved on: 
Wednesday, June 9, 2021
Medicine, Clinical medicine, Medical specialties, Neurosurgery, Computer-assisted surgery, Biopsy, Stereotactic surgery, Surgical oncology, Minimally invasive procedure, Surgeon

DUBAI, U.A.E, June 9, 2021 /PRNewswire/ -- The global stereotactic planning software spending analysis market is forecast to expand at 4.6% CAGR between 2021 and 2031, as per ESOMAR-certified consulting firm Future Market Insights (FMI).

Key Points: 
  • DUBAI, U.A.E, June 9, 2021 /PRNewswire/ -- The global stereotactic planning software spending analysis market is forecast to expand at 4.6% CAGR between 2021 and 2031, as per ESOMAR-certified consulting firm Future Market Insights (FMI).
  • Increasing demand for minimally-invasive treatment options has fueled the adoption of stereotactic planning software.
  • With the help of stereotactic planning software, surgeons will be able to perform surgery with reduced trajectory planning time.
  • COVID-19 pandemic hindered the stereotactic planning software spending market amid implementation of lockdown, limited production, and travel restrictions.

El Camino Health is First in California to Offer Cancer Patients Innovative Ethos™ Adaptive Intelligence™ Radiation Technology

Retrieved on: 
Tuesday, June 8, 2021
Medicine, Clinical medicine, Neurosurgery, Medical specialties, Radiobiology, Medical physics, Radiosurgery, Cyberknife, Radiation therapy, Draft:Surface Guided Radiation Therapy, Stereotactic surgery

"The speed, precision and accuracy of this new technology is reshaping how we fight cancer," said Dr. Robert Sinha, director of the Center for Advanced Radiotherapy and Cyberknife Radiosurgery at El Camino Health.

Key Points: 
  • "The speed, precision and accuracy of this new technology is reshaping how we fight cancer," said Dr. Robert Sinha, director of the Center for Advanced Radiotherapy and Cyberknife Radiosurgery at El Camino Health.
  • "We've never had the ability with radiation treatment to look inside the body and see what's changing in real time, until now.
  • Ethos is the only technology that can customize radiation treatment plans in real time based on individual patient needs and anatomical changes.
  • El Camino Health's cancer radiation therapy program offers leading-edge radiation treatment options that are typically found exclusively in large academic institutions.

RayStation latest release, ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­now with support for Accuray's CyberKnife® System

Retrieved on: 
Wednesday, May 26, 2021
Medicine, Clinical medicine, Medical specialties, Neurosurgery, Medical physics, Radiobiology, Radiation therapy, Radiosurgery, Cyberknife, Stereotactic surgery, Radiation treatment planning, Collimator

STOCKHOLM, May 26, 2021 /PRNewswire/ -- RaySearch announces the release of RayStation* 11A, the latest version of RaySearch's advanced treatment planning system.

Key Points: 
  • STOCKHOLM, May 26, 2021 /PRNewswire/ -- RaySearch announces the release of RayStation* 11A, the latest version of RaySearch's advanced treatment planning system.
  • Significant new functionality includes treatment planning for Accuray's CyberKnife System for radiosurgery and stereotactic body radiation therapy (SBRT).
  • RayStation provides support for optimization with the three different collimation types fixed cone, Iris and Incise Multileaf collimator and all CyberKnife tracking techniques for Synchrony real-time motion synchronization.
  • RaySearch markets the RayStation treatment planning system (TPS) and the oncology information system (OIS) RayCare.

The Radiosurgery Society® Establishes Residents Association to Optimize Educational Experience and Foster Future Leaders in SRS/SBRT

Retrieved on: 
Wednesday, May 19, 2021
Medicine, Clinical medicine, Medical specialties, Neurosurgery, Radiobiology, Radiosurgery, Stereotactic surgery, Radiation therapy, SRS, Radiation oncologist, Jay Loeffler

"\nRSSRA members have access to an array of opportunities for education, training, networking, and mentorship in the fields of SRS/SBRT that maximize both individual and group participation.

Key Points: 
  • "\nRSSRA members have access to an array of opportunities for education, training, networking, and mentorship in the fields of SRS/SBRT that maximize both individual and group participation.
  • Through the association, residents also have opportunities to do research, publish, present, and apply for various awards.
  • RSS Membership for residents and members-in-training is only $35/year.\nThe Radiosurgery Society (RSS) a non-profit, independent, multi-disciplinary organization of surgeons, radiation oncologists, physicists, and allied professionals, who are dedicated to advancing the science and clinical practice of radiosurgery.
  • Originally formed in 2002 and becoming 501(c)(6) in 2008, the Radiosurgery Society ( http://www.therss.org ) supports its members who perform stereotactic body radiotherapy and radiosurgery in hospitals and freestanding centers throughout the world.\n'

Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

Retrieved on: 
Monday, May 17, 2021
Medicine, Clinical medicine, Health sciences, Neurosurgery, Radiobiology, Radiation therapy, Radioactivity, Stereotactic surgery, Therapy, Cancer

GC4711 is a selective small molecule dismutase mimetic being developed to increase the anti-cancer effect of radiation.

Key Points: 
  • GC4711 is a selective small molecule dismutase mimetic being developed to increase the anti-cancer effect of radiation.
  • Secondary endpoints include progression-free survival (PFS), locoregional control (LRC), time to distant metastases (TDM) and surgical resection, in addition to safety.
  • GC4711 is in development specifically to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT).
  • A pilot Phase 1/2 trial of GC4419 in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported updated results, with follow-up ongoing.